Literature DB >> 11198934

Rational approach to the clinical protocol design for drug combinations: a review.

T T Chang1, T C Chou.   

Abstract

Based on the median-effect equation of Chou and the combination index (CI) equation of Chou-Talalay, a computer software for automated dose-effect analysis has been developed. This method provides quantitation of synergism (CI < 1) and antagonism (CI > 1) at different dose and effect levels. Therefore, it allows the selection of the best pair (or triplet) of combination, optimal combination ratio, and the best schedule of treatment. These analyses has been shown to be useful for the clinical protocol design. (Chang et al. Cancer Res. 45: 2434-2439, 1985). The user-friendly computer program also gives dose-reduction index (DRI) which determines how many fold of dose-reduction is allowed for each drug in synergistic combinations. Dose reduction leads to reduced toxicity while maintaining the desired efficacy (Chou et al. Encyclopedia of Human Biology 2:675-683, 1997; Encyclopedia of Cancer 1:368-379, 1997). The Chou-Talalay method distincts from all other methods by the fact that it not only takes into account the "potency" but also the "shape" of dose-effect curves of each drug and their combinations (Chou & Hayball, CalcuSyn for Windows, Biosoft, Cambridge UK, 1996). This method has been applied in combination of anticancer agents, anti-HIV agents, purging leukemic cells for autologous bone marrow transplantation (Chang et al. Cancer Res. 47:119-122, 1987) and combination of immunosuppressants for organs transplants. Specific examples of the theoretical equations, the median-effect plot, the CI plot, the isobologram, and the polygonogram are illustrated.

Entities:  

Mesh:

Year:  2000        PMID: 11198934

Source DB:  PubMed          Journal:  Acta Paediatr Taiwan        ISSN: 1608-8115


  17 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

Authors:  SubbaRao V Madhunapantula; Paul J Mosca; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

3.  Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).

Authors:  Scott D Seiwert; Steven W Andrews; Yutong Jiang; Vladimir Serebryany; Hua Tan; Karl Kossen; P T Ravi Rajagopalan; Shawn Misialek; Sarah K Stevens; Antitsa Stoycheva; Jin Hong; Sharlene R Lim; Xiaoli Qin; Robert Rieger; Kevin R Condroski; Hailong Zhang; Mary Geck Do; Christine Lemieux; Gary P Hingorani; Dylan P Hartley; John A Josey; Lin Pan; Leonid Beigelman; Lawrence M Blatt
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

4.  Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.

Authors:  Neil E Kay; Traci Sassoon; Charla Secreto; Sutapa Sinha; Tait D Shanafelt; Asish K Ghosh; Jack L Arbiser
Journal:  Leuk Lymphoma       Date:  2016-05-17

5.  Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.

Authors:  Asish K Ghosh; Neil E Kay; Charla R Secreto; Tait D Shanafelt
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

6.  Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model.

Authors:  Pedro M M Mesquita; Sarah S Wilson; Philippe Manlow; Lucia Fischetti; Marla J Keller; Betsy C Herold; Robin J Shattock
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

7.  Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.

Authors:  SubbaRao V Madhunapantula; Arati Sharma; Raghavendra Gowda; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2013-09-19       Impact factor: 4.693

8.  Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.

Authors:  Phillip Zook; Harsh B Pathak; Martin G Belinsky; Lawrence Gersz; Karthik Devarajan; Yan Zhou; Andrew K Godwin; Margaret von Mehren; Lori Rink
Journal:  Clin Cancer Res       Date:  2016-07-01       Impact factor: 12.531

9.  Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.

Authors:  Katarzyna Załuska-Ogryzek; Paweł Marzęda; Paula Wróblewska-Łuczka; Magdalena Florek-Łuszczki; Zbigniew Plewa; Hubert Bojar; Dorota Zolkowska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.

Authors:  Harsh B Pathak; Yan Zhou; Geetika Sethi; Jeff Hirst; Russell J Schilder; Erica A Golemis; Andrew K Godwin
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.